Konruns(SH:603590) Sou Hu Cai Jing·2025-08-20 10:04Core Viewpoint - Kangchen Pharmaceutical has experienced a decline in stock price over four consecutive trading days, with a cumulative drop of -6.28% [1] Company Overview - Founded in 2003, Beijing Kangchen Pharmaceutical Co., Ltd. focuses on innovative drug research and development, aiming to enhance human health through life sciences [1] - The company has developed into a high-tech pharmaceutical enterprise integrating research, production, and marketing, and was listed on the Shanghai Stock Exchange in August 2018 under the stock code 603590 [1] Financial Performance - The financial report indicates that Penghua Fund's Penghua Medical Technology Stock A has entered the top ten shareholders of Kangchen Pharmaceutical, marking a new entry in the second quarter of this year [1] - The fund has achieved a year-to-date return of 94.36%, ranking 7th among its peers out of a total of 979 funds [1][2] Fund Manager Profile - The fund manager of Penghua Medical Technology Stock A is Jin Xiaofei, who has been with Penghua Fund Management since July 2012 and has held various positions, including senior researcher and deputy general manager of equity investment [3][4] - Jin has managed multiple funds, including the Penghua Medical Technology Stock Fund since June 2016, and has a strong background in industry research [3][4]